期刊文献+

急性心肌梗死患者无复流现象与降低血浆胆固醇的临床探究 被引量:4

Clinica Explore No Reflow Phenomenon in Patients With Acute Myocardial Infarction and Lowering Plasma Cholesterol
下载PDF
导出
摘要 目的急性心肌梗死患者无复流现象与降低血浆胆固醇的临床分析。方法选取我院2012年10月~2014年10月收治的急性心肌梗死患者66例,均行经皮冠状动脉成形术(PCI)进行治疗,并依据术后有无复流情况,分为NSN组14例,NSNN组30例,SN组2例,SNN组20例,并对无复流组与复流组血浆的LDL-C和TC水平进行比较。结果未使用他汀治疗与使用他汀治疗发生无复流情况的比较,差异具有统计学意义(P〈0.05);SNN+NSNN组与SN+NSN组LDL-C和TC水平的比较,差异具有统计学意义(P〈0.05)。结论急性心肌梗死再灌注治疗后无复流现象的发生与血脂水平有一定关系,他汀类药物的应用对无复流现象的改善具有良好的效果,且血浆胆固醇水平较低者无复流现象的发生率较低。 Objective Clinical analysis the no reflow phenomenon in patients with acute myocardial infarction and clinical analysis of reducing plasma cholesterol.Methods PCI from October 2012 to October 2014 in our hospital,66 cases of acute myocardial infarction patients after surgery according to have no reflow,NSN group 14 cases,NSNN group 30 cases of SN group and 2 cases,SNN group(20 cases) to compare the plasma levels of TC and LDL-C level.Results The use of statin and non statin treatment of no reflow of comparison,SNN+NSNN group and SN+NSN LDL-C and TC levels were compared with statistical difference(P〈0.05).ConclusionAfter reperfusion no reflow phenomenon of occurrence and serum lipid levels,statin drugs can improve the no reflow phenomenon,lowering plasma cholesterol can prevent reflow phenomenon occurs.
作者 彭娜娜
出处 《中国继续医学教育》 2016年第10期101-102,共2页 China Continuing Medical Education
关键词 血浆胆固醇 复流 心肌梗死 Plasma cholesterol Complex flow Myocardial infarction
  • 相关文献

参考文献6

二级参考文献37

  • 1孙菁,沈洪.急性心肌梗死患者冠状动脉再通后无复流相关因素的分析[J].中国全科医学,2009,12(7):551-553. 被引量:20
  • 2Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:346
  • 3李丽丽,贾大林.急性心肌梗死急诊PCI支架术后无复流现象的临床分析[J].临床和实验医学杂志,2007,6(7):21-22. 被引量:7
  • 4Resnic FS, Wainstein M, Lee MKY,et al. No-reflow is an inde- pendent predictor of death and myocardial infarction after percuta- neous coronary intervention. Am Heart J,2003,145 ( 1 ) :42-46.
  • 5Dayal S, Aming E, Bottiglieri T, et al. Cerebral vascular dys-func- tion mediated by superoxide in hyperhomocysteinemiamice. Stroke ,2004,35 ( 8 ) : 1957-1962.
  • 6Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during pri- mary percutaneous coronary intervention for acute myocardial in- farction on six-month mortality. Am J cardiol, 2007,99 ( 4 ) : 442- 445.
  • 7Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high- risk acute coronary syndromes treated with percutaneous coronary interventionsthe EVEREST trial. J Am College Cardiol, 2006,47 (3) :522-528.
  • 8李建平,霍勇,刘平,秦献辉,关德明,葛均波,胡健,王燕妮,张馥敏,毛广运,徐希平.马来酸依那普利叶酸片降压、降同型半胱氨酸的疗效和安全性[J].北京大学学报(医学版),2007,39(6):614-618. 被引量:390
  • 9Niccoli G,Burzotta F,Galiuto L,et al. Myocardial no-reflow in humans[J]. J AM Cardiol,2009, 54(4):281-92.
  • 10Kim JS,Kim J,Choi D,et al. Efficacy of high-dose atorvastatin loading before primary peutaneous coronary intervention in ST-segment elevation myocardial infarction:the STATIN STEMI trial[J]. JACC Cardiovasc Interv,2010,3(3):332-9.

共引文献35

同被引文献35

  • 1颜红兵,刘景山,张坚,郭诗东,高焱莎,柯元南.直接冠状动脉介入治疗支架内血栓形成的发生率、危险因素及预后[J].中国介入心脏病学杂志,2004,12(3):135-138. 被引量:16
  • 2郭路芬,彭亚光,李庆祥,贺建华,赵冬,洪昭光.急性心肌梗死发病至就诊时间与预后的关系[J].中华心血管病杂志,2007,35(1):40-43. 被引量:76
  • 3Levine GN,O'Gara PT,Bates ER,et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of Cardiology/American heart association task force on clinical practice cuidelines and the society for cardiovascular angiography and interventions [J~. J Am Coil Cardiol, 2015,1097 ( 15 ) : 6797-6802.
  • 4Salins P,Jimenez-Valevo S,Moreno R,et al-Update in pharmacolo- logical management of coronary no-reflow phenomenon[J]. Car- diovasc Hematol Agents Med Chem,2012,10(3) :256-264.
  • 5Oduncu V,Tanalp AC,Erkol A,et al.Impact of chronic pre- treatment of statins on the level of systemic inflammation and myocardial perfusion in patients undergoing primary angioplasty [J].Am J Cardiol,2011,107(2) : 179-185.
  • 6Brosh D,Assali AR,Mager A,et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality [J~.Am J Cardiol,2007,99 (4) :442-445.
  • 7Wislon RF,Laxson DD,Lesser JR,et al. Intense microvaseual constriction after angioplasty of acute thrombotic coronary artery lesions[ J~. Lancet, 1989,1 : 807-811.
  • 8Movahed MR,Butman SM. The pathogenesis and treatment of no-flow occurring during percutaneous coronary intervention [J]. Cardiovasc Revase Med, 2008,9: 56-61.
  • 9Wong DT,Puri R, Richardson JD, et al. Myocardial "no-reflow" diagnosis,pathophysiology and treatment [J]. Int J Cardiol, 2013,167(5) : 1798-1806.
  • 10Hao PP,Chen YG,Wang JL,et al.Meta-analysis of the role of high-dose statins and ministered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease [J]. Clin Exp Pharmacul Physiol, 2010,37(4) : 496-500.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部